Archive for the ‘Isis Pharmaceuticals’ Category

Ionis Pharmaceuticals

January 25th, 2016 | Posted in 2016, Ionis Pharmaceuticals, Isis Pharmaceuticals

Ionis Pharmaceuticals, formerly Isis Pharmaceuticals, has been granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington’s disease. The Orphan Drug Designation entitles the company to seven years of market exclusivity in the U.S. if the drug candidate reaches the market. The designation is part of the Orphan Drug Act, which provides […]

Ionis Pharmaceuticals

December 22nd, 2015 | Posted in 2015, Ionis Pharmaceuticals, Isis Pharmaceuticals

Carlsbad-based Isis Pharmaceuticals is changing its name to Ionis Pharmaceuticals. The company is also changing its Nasdaq stock symbol from ISIS to IONS, and its website address to www.ionispharma.com. While it didn’t spell out the reason for the name change, ISIS is also the acronym for Islamic State of Iraq and al-Sham, an Islamic fundamentalist terrorist group. […]

Isis Pharmaceuticals

February 24th, 2015 | Posted in 2015, Isis Pharmaceuticals

Isis Pharmaceuticals, Carlsbad, earned a $5 million milestone payment from Biogen Idec related to developing a treatment for a neurological disorder. Isis has generated $305 million through four collaborations with Biogen Idec.

Isis Pharmaceuticals

July 18th, 2014 | Posted in 2014, Isis Pharmaceuticals

Isis Pharmaceuticals, Carlsbad, earned a $1 Million payment from GlaxoSmithKline in relation to its program to develop treatments for the hepatitis B virus. To date, Glaxo has paid Isis $11 Million for the program which has led to three new drugs in the pipeline.

Isis Pharmaceuticals

September 12th, 2013 | Posted in 2013, Isis Pharmaceuticals

Isis Pharmaceuticals, Carlsbad, CA and Biogen Idec:  have struck a “mega-alliance” to develop drugs for neurological diseases using its gene-blocking antisense technology.   The partnership, recently announced, in which Isis will get $100-million upfront and milestone payments of up to $220-million per drugs, along with Phase 1 and 2 clinical trial expenses of about $30-million per drug.  […]

Isis Pharmaceuticals, Carlsbad, CA

April 9th, 2013 | Posted in 2013, Isis Pharmaceuticals

Will receive $30-milion upfront for a potential $362-million alliance with Roche to develop a drug for Huntington’s disease, an invariably fatal genetic illness.  Roche, based in Basel, Switzerland, is a major pharmaceutical giant.